Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan spots chemo damage to heart and muscles early

NCT ID NCT05731375

Knowledge-focused Sponsor: UMC Utrecht Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special MRI scan (31P-MRS) can detect early signs of damage to heart and muscle cells caused by chemotherapy drugs like doxorubicin. Twelve cancer patients scheduled for chemo underwent three scans over time. The goal was to see if the scan could measure changes in energy production inside cells, which might help doctors catch problems before they become serious.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a non-invasive way to detect early chemotherapy-related heart and muscle damage, helping doctors adjust treatment sooner.
What could go wrong
This is a very small, completed observational study with only 12 participants. It does not test any treatment, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

12 people

The number who actually took part.

Started

Dec 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will be recruited at UMC Utrecht, Diakonessenhuis Utrecht and possibly other hospitals in the vincity of the UMC Utrecht. The aim is to include 12 patients with with any type of cancer scheduled to receive treatment with anthracyclines and/or platinum-based drugs at any of the recruiting hospitals.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age ≥ 18 years * Patients diagnosed with any type of cancer, who are scheduled to receive chemotherapy treatment containing at least anthracyclines and/or platinum-based drugs. * WHO-performance score 0-2. * Patients with sufficient Dutch writing and reading skills. * Written informed consent. Exclusion Criteria: * Contra-indications for 7T MR scanning, including patients with a non-MRI compatible pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; patients with a non-MR compatible aneurysm clip in their brain; patients with claustrophobia, and/or severe obesity. * Any circumstances that would impede adherence to study requirements or ability to give informed consent. * Medical disorders affecting mitochondrial function; e.g., spinal muscular atrophy. * (Other) relevant medical disorders; e.g., comorbidities affecting exercise tolerance. * Being under examination for non-diagnosed disease at the time of investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracyclines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer cardiomyopathy due to anthracyclines chemotherapy-induced toxicity doxorubicin induced cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracyclines Chemotherapeutic toxicity Doxorubicin induced cardiomyopathy

Contacts and locations

Locations

  • Diakonessenhuis

    Utrecht, Utrecht, 3582 KE, Netherlands

  • Meander Medisch Centrum

    Amersfoort, Utrecht, 3813 TZ, Netherlands

  • UMC Utrecht

    Utrecht, Utrecht, 3584CX, Netherlands

  • Ziekenhuis Gelderse Vallei

    Ede, Gelderland, 6716 RP, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.